40 completed, 4 terminated. 20 Phase 3, 16 Phase 2, 8 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 20 | Completed 19, Terminated 1 |
| Phase 2 | 16 | Completed 14, Terminated 2 |
| Phase 1 | 8 | Completed 7, Terminated 1 |
Follow Comparator: placebo (unspecified): new trials by email Literature Review of Comparator: placebo (unspecified) trials Research Report on Comparator: placebo (unspecified)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041) Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine, Comparator: placebo (unspecified) - HPV Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 3006 | 2008-12-31 | 2019-02-04 |
| MK3207 for Treatment of Acute Migraines (3207-005) MK3207- 2.5 mg, MK3207- 5 mg, MK3207- 10 mg - Migraine | Phase 2 | Completed | Merck Sharp & Dohme LLC | 676 | 2008-07-01 | 2015-02-02 |
| Study of Inhaled Corticosteroid Plus Montelukast Compared With Inhaled Corticosteroid Therapy Alone in Patients With Chronic Asthma (0476-386) Comparator: mometasone, Comparator: montelukast, Comparator: placebo (unspecified) - Asthma | Phase 2 | Completed | Organon and Co | 134 | 2008-05-01 | 2024-05-10 |
| A Research Study of MK0633 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0633-009)(COMPLETED) MK633, Comparator: Placebo (unspecified) - Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Completed | Merck Sharp & Dohme LLC | 266 | 2008-01-01 | 2015-09-03 |
| Neuropathic Pain Syndrome Patient Study (MK-0000-072) Comparator: pregabalin, Comparator: Placebo (unspecified) - Neuralgia, Postherpetic, Diabetic Neuropathy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 104 | 2007-12-01 | 2015-05-07 |
| MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016) MK0249, Comparator: Placebo (unspecified) - Paranoid Schizophrenia | Phase 2 | Completed | Merck Sharp & Dohme LLC | 55 | 2007-12-01 | 2015-08-03 |
| A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED) V504, Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine, Comparator: Placebo (unspecified) - Cervical Cancer, Vulvar Cancer | Phase 2 | Completed | Merck Sharp & Dohme LLC | 620 | 2007-10-01 | 2015-06-08 |
| A Study to Determine the Effectiveness and Tolerability of MK8141 in Patients With High Blood Pressure (MK-8141-006) MK8141, Comparator: placebo (unspecified), Enalapril - Hypertension | Phase 2 | Completed | Merck Sharp & Dohme LLC | 160 | 2007-10-01 | 2015-10-16 |
| Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001) Comparator: V505 formulation 1, Comparator: V505 formulation 2, Comparator: V505 formulation 3 - Cervical Cancer, Vulvar Cancer | Phase 2 | Completed | Merck Sharp & Dohme LLC | 511 | 2007-10-01 | 2015-11-26 |
| MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027) MK0557, Comparator: Placebo (unspecified) - Paranoid Schizophrenia, Schizophrenia | Phase 2 | Completed | Merck Sharp & Dohme LLC | 50 | 2007-09-01 | 2015-08-21 |
| Placebo-Controlled Randomized Study of KW-3902 for Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring IV Therapy rolofylline, Comparator: Placebo (unspecified) - Heart Failure, Congestive | Phase 3 | Completed | NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 480 | 2007-08-01 | 2009-02-20 |
| A Study of Gastric Delay in Migraine Patients (3207-003) MK3207, Comparator: Placebo (unspecified) - Migraine Disorders | Phase 1 | Completed | Merck Sharp & Dohme LLC | 22 | 2007-08-01 | 2014-12-19 |
| A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED) vorinostat, Comparator: placebo (unspecified) - Advanced Cancer Relapsed, Advanced Cancer Refractory | Phase 1 | Completed | Merck Sharp & Dohme LLC | 25 | 2007-07-01 | 2015-07-30 |
| A Study of MK0657 in Parkinson's Disease Patients (0657-006) MK0657, Comparator: Placebo (unspecified), Comparator: levodopa - Parkinson's Disease | Phase 1 | Completed | Merck Sharp & Dohme LLC | 18 | 2007-05-01 | 2015-01-29 |
| Exercise Induced Bronchoconstriction (0476-359) montelukast sodium, Comparator: placebo (unspecified) - Asthma, Exercise-induced | Phase 1 | Completed | Organon and Co | 24 | 2007-05-01 | 2024-05-09 |
| A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED) MK-0736, Comparator: placebo (unspecified) - Peripheral Vascular Diseases | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 14 | 2007-03-31 | 2018-08-17 |
| Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059) Comparator: sitagliptin phosphate, Comparator: placebo (unspecified) - Type 2 Diabetes Mellitus (T2DM) | Phase 1 | Completed | Merck Sharp & Dohme LLC | 57 | 2007-02-14 | 2017-05-12 |
| A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED) ezetimibe (+) simvastatin, Comparator : rosuvastatin calcium, Comparator: Placebo (unspecified) - Hypercholesterolemia | Phase 3 | Completed | Organon and Co | 618 | 2007-02-01 | 2024-05-16 |
| Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED) ezetimibe (+) simvastatin, Comparator: atorvastatin calcium, Comparator: Placebo (unspecified) - Hypercholesterolemia, Metabolic Syndrome | Phase 3 | Completed | Organon and Co | 1143 | 2007-01-01 | 2024-05-16 |
| V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028) Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501), Comparator: Placebo (unspecified) - HPV Infections | Phase 2 | Completed | Merck Sharp & Dohme LLC | 107 | 2006-12-11 | 2017-04-21 |
Showing 20 of 44. Sign in to see all of them.
Diabetes Mellitus, Type 2 (5) · Depressive Disorder, Major (4) · Papillomavirus Infections (4) · Asthma (3) · Condylomata Acuminata (3) · Heart Failure (3) · Renal Insufficiency (3) · Hypercholesterolemia (2) · Migraine Disorders (2) · Schizophrenia, Paranoid (2) · Sleep Initiation and Maintenance Disorders (2) · Uterine Cervical Neoplasms (2) · Vaginal Neoplasms (2) · Vulvar Neoplasms (2) · Alzheimer Disease (1)
Merck Sharp & Dohme LLC (30) · Organon and Co (9) · NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (3) · H. Lundbeck A/S (2)
Barry Massie, MD (3) · Christopher O'Connor, MD (3) · Marco Metra, MD (2)
PMID 18926433, PMID 20925544, PMID 21545947, PMID 21900185, PMID 22339573, PMID 24281134, PMID 24281137, PMID 27448534, PMID 27658757, PMID 29748350, PMID 41276263, PMID 19380898, PMID 19491335, PMID 19887475, PMID 20191935, PMID 20306820, PMID 20332588, PMID 20705534, PMID 20970976, PMID 21050476, PMID 21185118, PMID 21288094, PMID 21383045, PMID 21448918, PMID 21545249, PMID 21624752, PMID 21859750, PMID 22029979, PMID 22108151, PMID 22154769, PMID 22272611, PMID 22685234, PMID 23523692, PMID 23831322, PMID 26336957, PMID 27266853, PMID 27507112, PMID 28069685, PMID 28624483, PMID 29059133, PMID 30638797, PMID 31926466, PMID 32184277, PMID 32827835, PMID 34265048, PMID 34780705, PMID 38012959, PMID 41162330, PMID 41400842
2004 (1)